Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'

被引：4

作者：

Wang, Bin ^{[1
]}

Chen, Shiju ^{[1
]}

Xuan, Jingxiu ^{[1
]}

Li, Yan ^{[1
]}

Zheng, Qing ^{[1
]}

Zhang, Xinwei ^{[1
]}

Liu, Yuan ^{[1
]}

Shi, Guixiu ^{[1
,2
]}

机构：

[1] Xiamen Univ, Affiliated Hosp 1, Dept Rheumatol & Clin Immunol, Xiamen, Peoples R China

[2] Xiamen Key Lab Rheumatol & Clin Immunol, Dept Sci & Technol, Xiamen, Peoples R China

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷 / 03期

基金：

中国博士后科学基金;

关键词：

D O I：

10.1136/annrheumdis-2020-219666

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：2

共 50 条

[21] Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Wang, Yeming
Zhang, Dingyu
Du, Guanhua
Du, Ronghui
Zhao, Jianping
Jin, Yang
Fu, Shouzhi
Gao, Ling
Cheng, Zhenshun
Lu, Qiaofa
Hu, Yi
Luo, Guangwei
Wang, Ke
Lu, Yang
Li, Huadong
Wang, Shuzhen
Ruan, Shunan
Yang, Chengqing
Mei, Chunlin
Wang, Yi
Ding, Dan
Wu, Feng
Tang, Xin
Ye, Xianzhi
Ye, Yingchun
Liu, Bing
Yang, Jie
Yin, Wen
Wang, Aili
Fan, Guohui
Zhou, Fei
Liu, Zhibo
Gu, Xiaoying
Xu, Jiuyang
Shang, Lianhan
Zhang, Yi
Cao, Lianjun
Guo, Tingting
Wan, Yan
Qin, Hong
Jiang, Yushen
Jaki, Thomas
Hayden, Frederick G.
Horby, Peter W.
Cao, Bin
Wang, Chen
LANCET, 2020, 395 (10236): : 1569 - 1578
[22] Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial
Machado, Pedro M.
McDermott, Michael P.
Blaettler, Thomas
Sundgreen, Claus
Amato, Anthony A.
Ciafaloni, Emma
Freimer, Miriam
Gibson, Summer B.
Jones, Sarah M.
Levine, Todd D.
Lloyd, Thomas E.
Mozaffar, Tahseen
Shaibani, Aziz, I
Wicklund, Matthew
Rosholm, Anders
Carstensen, Tim Dehli
Bonefeld, Karen
Jorgensen, Anders Norkaer
Phonekeo, Karina
Heim, Andrew J.
Herbelin, Laura
Barohn, Richard J.
Hanna, Michael G.
Dimachkie, Mazen M.
LANCET NEUROLOGY, 2023, 22 (10): : 900 - 911
[23] Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial
Brusselle, Guy G.
VanderStichele, Christine
Jordens, Paul
Deman, Rene
Slabbynck, Hans
Ringoet, Veerle
Verleden, Geert
Demedts, Ingel K.
Verhamme, Katia
Delporte, Anja
Demeyere, Benedicte
Claeys, Geert
Boelens, Jerina
Padalko, Elizaveta
Verschakelen, Johny
Van Maele, Georges
Deschepper, Ellen
Joos, Guy F. P.
THORAX, 2013, 68 (04) : 322 - 329
[24] A multicentre, randomised, double-blind, placebo-controlled trial of aminophylline for bronchiolitis in infants admitted to intensive care
Turner, Alastair
Shann, Frank
Delzoppo, Carmel
Henning, Robert
Slater, Anthony
Beca, John
Erickson, Simon
Butt, Warwick
CRITICAL CARE AND RESUSCITATION, 2014, 16 (03) : 220 - 224
[25] Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial
Thwaites, Guy E.
Scarborough, Matthew
Szubert, Alexander
Nsutebu, Emmanuel
Tilley, Robert
Greig, Julia
Wyllie, Sarah A.
Wilson, Peter
Auckland, Cressida
Cairns, Janet
Ward, Denise
Lal, Pankaj
Guleri, Achyut
Jenkins, Neil
Sutton, Julian
Wiselka, Martin
Armando, Gonzalez-Ruiz
Graham, Clive
Chadwick, Paul R.
Barlow, Gavin
Gordon, N. Claire
Young, Bernadette
Meisner, Sarah
McWhinney, Paul
Price, David A.
Harvey, David
Nayar, Deepa
Jeyaratnam, Dakshika
Planche, Tim
Minton, Jane
Hudson, Fleur
Hopkins, Susan
Williams, John
Torok, M. Estee
Llewelyn, Martin J.
Edgeworth, Jonathan D.
Walker, A. Sarah
LANCET, 2018, 391 (10121): : 668 - 678
[26] Efficacy and safety of telitacicept in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial
Xu, Dong
Fang, Jianmin
Zhang, Shangzhu
Huang, Cibo
Huang, Chenghui
Qin, Li
Li, Xiaomei
Chen, Meiqing
Liu, Xiumei
Liu, Yi
Li, Zhijun
Hu, Jiankang
Bao, Chunde
Wei, Wei
Tian, Jing
Duan, Xinwang
Zeng, Xiaofeng
RHEUMATOLOGY, 2024, 63 (03) : 698 - 705
[27] Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial
Sun, Fangfang
Wang, Hui Jing
Liu, Zhe
Geng, Shikai
Wang, Haiting
Wang, Xiaodong
Li, Ting
Morel, Laurence
Wan, Weiguo
Lu, Liangjing
Teng, Xiangyu
Ye, Shuang
LANCET RHEUMATOLOGY, 2020, 2 (04): : E210 - E216
[28] Efficacy and Safety of Telitacicept in Primary Sjogren's Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial
Xu, Dong
Zhang, Shangzhu
Huang, Cibo
Huang, Chenghui
Qin, Li
Li, Xiaomei
Chen, Meiqing
Liu, Xiumei
Liu, Yi
Li, Zhijun
Hu, Jiankang
Bao, Chunde
Wei, Wei
Tian, Jing
Duan, Xinwang
Fang, Jianmin
Zeng, Xiaofeng
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4002 - 4004
[29] Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial
Kloppenburg, Margreet
Ramonda, Roberta
Bobacz, Klaus
Kwok, Wing-Yee
Elewaut, Dirk
Huizinga, Tom W. J.
Kroon, Feline P. B.
Punzi, Leonardo
Smolen, Josef S.
Cruyssen, Bert Vander
Wolterbeek, Ron
Verbruggen, Gust
Wittoek, Ruth
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (12) : 1757 - 1764
[30] Traditional Chinese Medicine in Patients With Primary Sjogren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Chen, Huang-Hsi
Lai, Jung-Nien
Yu, Min-Chien
Chen, Chia-Yin
Hsieh, Yi-Ting
Hsu, Yi-Fan
Wei, James Cheng-Chung
FRONTIERS IN MEDICINE, 2021, 8

← 1 2 3 4 5 →